Vigil Neuroscience logo

Vigil NeuroscienceNASDAQ: VIGL

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

07 January 2022

Next earnings report:

07 November 2024

Last dividends:

N/A

Next dividends:

N/A
$153.44 M
-73%vs. 3y high
49%vs. sector
-vs. 3y high
-vs. sector
-36%vs. 3y high
54%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Fri, 01 Nov 2024 20:02:15 GMT
$3.87+$0.09(+2.38%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

VIGL Latest News

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL)
prnewswire.com09 October 2024 Sentiment: NEGATIVE

NEW YORK , Oct. 9, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Vigil Neuroscience, Inc. (NASDAQ: VIGL) on behalf of the company's shareholders.  The investigation seeks to determine whether Vigil Neuroscience's directors breached their fiduciary duties in connection with recent corporate actions.

Vigil Neuroscience to Present at Upcoming September Investor Conferences
globenewswire.com29 August 2024 Sentiment: POSITIVE

WATERTOWN, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that members of management will present at two upcoming investor conferences.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL)
prnewswire.com23 August 2024 Sentiment: NEGATIVE

NEW YORK , Aug. 23, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Vigil Neuroscience, Inc. (NASDAQ: VIGL) on behalf of the company's shareholders. The investigation seeks to determine whether Vigil Neuroscience's directors breached their fiduciary duties in connection with recent corporate actions.

Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update
globenewswire.com13 August 2024 Sentiment: POSITIVE

- Announced $40 million strategic investment from Sanofi; Extended cash runway into 2026 - - Provided update on iluzanebart clinical development strategy to pursue potential accelerated approval pathway in ALSP - - Announced interim data from VG-3927 Phase 1 trial in healthy volunteers that support continued development as potential therapy for Alzheimer's disease - WATERTOWN, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2024, and provided an update on recent progress.

Vigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International Conference
globenewswire.com18 July 2024 Sentiment: POSITIVE

WATERTOWN, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced one oral and two poster presentations highlighting its oral small molecule VG-3927 at the 2024 Alzheimer's Association International Conference (AAIC) taking place on July 28-August 1, 2024 in Philadelphia, Pennsylvania and virtually.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL)
prnewswire.com08 July 2024 Sentiment: NEGATIVE

NEW YORK , July 8, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Vigil Neuroscience, Inc. (NASDAQ: VIGL) on behalf of the company's shareholders. The investigation seeks to determine whether Vigil Neuroscience's directors breached their fiduciary duties in connection with recent corporate actions.

Why Is Vigil Neuroscience (VIGL) Stock Up 32% Today?
investorplace.com27 June 2024 Sentiment: POSITIVE

Vigil Neuroscience (NASDAQ: VIGL ) stock is soaring higher on Thursday after the clinical-stage biotechnology company revealed a $40 million strategic investment from Sanofi (NASDAQ: SNY ). This investment has Sanofi purchasing 537,634 shares of Series A non-voting preferred shares at a price of $7.44 each.

Augustine Therapeutics Raises EUR 17 Million in a Series A First Closing to Advance Lead Candidate Into Clinical Development in Neurological Diseases
businesswire.com26 June 2024 Sentiment: POSITIVE

LEUVEN, Belgium--(BUSINESS WIRE)-- #ALS--Augustine Therapeutics, a pioneering biotech company focused on novel treatments for neurodegenerative and cardiometabolic diseases, today announced that it has raised EUR 17 million (USD 18.5 million) in the first closing of its Series A round. The financing was led by Asabys Partners, with participation from Eli Lilly and Company, and the US-based Charcot-Marie-Tooth Research Foundation. Current investors AdBio partners, V-Bio Ventures, PMV, VIB and Gemma Fri.

Vigil Neuroscience to Present in Upcoming June Investor Conferences
globenewswire.com30 May 2024 Sentiment: POSITIVE

WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced management's participation at two upcoming investor conferences.

All You Need to Know About Vigil Neuroscience (VIGL) Rating Upgrade to Buy
zacks.com28 May 2024 Sentiment: POSITIVE

Vigil Neuroscience (VIGL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What type of business is Vigil Neuroscience?

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

What sector is Vigil Neuroscience in?

Vigil Neuroscience is in the Healthcare sector

What industry is Vigil Neuroscience in?

Vigil Neuroscience is in the Biotechnology industry

What country is Vigil Neuroscience from?

Vigil Neuroscience is headquartered in United States

When did Vigil Neuroscience go public?

Vigil Neuroscience initial public offering (IPO) was on 07 January 2022

What is Vigil Neuroscience website?

https://www.vigilneuro.com

Is Vigil Neuroscience in the S&P 500?

No, Vigil Neuroscience is not included in the S&P 500 index

Is Vigil Neuroscience in the NASDAQ 100?

No, Vigil Neuroscience is not included in the NASDAQ 100 index

Is Vigil Neuroscience in the Dow Jones?

No, Vigil Neuroscience is not included in the Dow Jones index

When was Vigil Neuroscience the previous earnings report?

No data

When does Vigil Neuroscience earnings report?

The next expected earnings date for Vigil Neuroscience is 07 November 2024